Global & regional health technology assessment · 2026
[Not Available].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perrone Valentina, Leonetti Simone, Esposti Luca Degli, Giannessi Lisa, Guerzoni Simona, Entities group
Аннотация
INTRODUCTION:: This retrospective observational analysis evaluated the clinical, demographic, and economic burden of migraine patients in real-world Italian clinical practice.
METHODS:: A retrospective observational analysis was conducted using Italian administrative databases, involving approximately 12 million beneficiaries. All adult patients with at least one hospital discharge diagnosis of migraine (ICD-9-CM = 346) or at least one prescription for migraine-specific medications (ATC = N02C) between January 2010 and July 2024 were included. The index-date was defined as the first occurrence of either inclusion criterion. Patients were characterized at baseline for demographic variables and comorbidity profile. Direct healthcare costs covered by the National Health Service (SSN) were estimated per patient for the 12 months pre- and post-index-date. An exploratory analysis of total direct healthcare costs was performed, including both migraine-specific and potentially migraine-related costs, over three-time horizons (12, 36, and 60 months before the index-date). Analyses were stratified by sex.
RESULTS:: A total of 185,737 patients were included; 72.1% were female, with a mean age of 47 years. Of the patients, 75.3% had no relevant comorbidities (Charlson Comorbidity Index = 0). The total healthcare costs per patient were estimated at € 898 and € 1,179 in the 12 months before and after the index-date, respectively. Hospitalization and outpatient service costs potentially related to migraine were approximately ten times higher than migraine-specific costs.
CONCLUSIONS:: Migraine imposes a significant economic burden, particularly among the female population. Exploratory analyses revealed that potentially migraine-related costs were higher than migraine-specific costs, suggesting a delay in diagnosis and appropriate management.
METHODS:: A retrospective observational analysis was conducted using Italian administrative databases, involving approximately 12 million beneficiaries. All adult patients with at least one hospital discharge diagnosis of migraine (ICD-9-CM = 346) or at least one prescription for migraine-specific medications (ATC = N02C) between January 2010 and July 2024 were included. The index-date was defined as the first occurrence of either inclusion criterion. Patients were characterized at baseline for demographic variables and comorbidity profile. Direct healthcare costs covered by the National Health Service (SSN) were estimated per patient for the 12 months pre- and post-index-date. An exploratory analysis of total direct healthcare costs was performed, including both migraine-specific and potentially migraine-related costs, over three-time horizons (12, 36, and 60 months before the index-date). Analyses were stratified by sex.
RESULTS:: A total of 185,737 patients were included; 72.1% were female, with a mean age of 47 years. Of the patients, 75.3% had no relevant comorbidities (Charlson Comorbidity Index = 0). The total healthcare costs per patient were estimated at € 898 and € 1,179 in the 12 months before and after the index-date, respectively. Hospitalization and outpatient service costs potentially related to migraine were approximately ten times higher than migraine-specific costs.
CONCLUSIONS:: Migraine imposes a significant economic burden, particularly among the female population. Exploratory analyses revealed that potentially migraine-related costs were higher than migraine-specific costs, suggesting a delay in diagnosis and appropriate management.